Skip to main content

Liraglutide vs Survodutide

Both Liraglutide and Survodutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Liraglutide

Evidence A+

Liraglutide (Saxenda / Victoza)

The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.

View full Liraglutide profile →

Survodutide

Evidence A

Survodutide (BI 456906)

A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.

View full Survodutide profile →

Side-by-Side

AttributeLiraglutideSurvodutide
Evidence GradeA+A
FDA StatusFDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza)Not FDA-approved — Phase 3 trials for obesity and MASH
Typical Dose0.6–3.0 mg daily (subcutaneous)Trial range: 0.6–6 mg weekly (subcutaneous)
Clinics Indexed5406
Categoriesweight-loss, metabolicweight-loss, metabolic

Key reported benefits — Liraglutide

  • Weight loss
  • Appetite suppression
  • Glycemic control

Key reported benefits — Survodutide

  • Weight loss
  • MASH resolution
  • Glucose control

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons